32 related articles for article (PubMed ID: 12782478)
1. Oral bacteria as potential probiotics for the pharyngeal mucosa.
Guglielmetti S; Taverniti V; Minuzzo M; Arioli S; Stuknyte M; Karp M; Mora D
Appl Environ Microbiol; 2010 Jun; 76(12):3948-58. PubMed ID: 20418429
[TBL] [Abstract][Full Text] [Related]
2. Mucolytic and Antioxidant Properties of Carbocysteine as a Strategy in COVID-19 Therapy.
Bianco A; Conte S; Mariniello DF; Allocca V; Matera MG; D'Agnano V; Lanata L; Cazzola M; Perrotta F
Life (Basel); 2022 Nov; 12(11):. PubMed ID: 36362979
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Potential of Small Molecules Targeting Oxidative Stress in the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comprehensive Review.
Dailah HG
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080309
[TBL] [Abstract][Full Text] [Related]
4. Clinical Efficacy of Carbocysteine in COPD: Beyond the Mucolytic Action.
Pace E; Cerveri I; Lacedonia D; Paone G; Sanduzzi Zamparelli A; Sorbo R; Allegretti M; Lanata L; Scaglione F
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745833
[TBL] [Abstract][Full Text] [Related]
5. S-Carboxymethyl Cysteine Protects against Oxidative Stress and Mitochondrial Impairment in a Parkinson's Disease In Vitro Model.
Catanesi M; Brandolini L; d'Angelo M; Tupone MG; Benedetti E; Alfonsetti M; Quintiliani M; Fratelli M; Iaconis D; Cimini A; Castelli V; Allegretti M
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680584
[TBL] [Abstract][Full Text] [Related]
6. Conventional and Nanotechnology Based Approaches to Combat Chronic Obstructive Pulmonary Disease: Implications for Chronic Airway Diseases.
Passi M; Shahid S; Chockalingam S; Sundar IK; Packirisamy G
Int J Nanomedicine; 2020; 15():3803-3826. PubMed ID: 32547029
[TBL] [Abstract][Full Text] [Related]
7. Respiratory Barrier as a Safeguard and Regulator of Defense Against Influenza A Virus and
LeMessurier KS; Tiwary M; Morin NP; Samarasinghe AE
Front Immunol; 2020; 11():3. PubMed ID: 32117216
[TBL] [Abstract][Full Text] [Related]
8. Mucoactive and antioxidant medicines for COPD: consensus of a group of Chinese pulmonary physicians.
Yan X; Song Y; Shen C; Xu W; Chen L; Zhang J; Liu H; Huang M; Lai G; Qian G; Wang J; Ye X; Zheng J; Bai C
Int J Chron Obstruct Pulmon Dis; 2017; 12():803-812. PubMed ID: 28405161
[TBL] [Abstract][Full Text] [Related]
9. Strategies to decrease ongoing oxidant burden in chronic obstructive pulmonary disease.
Rahman I; Kinnula VL
Expert Rev Clin Pharmacol; 2012 May; 5(3):293-309. PubMed ID: 22697592
[TBL] [Abstract][Full Text] [Related]
10. Antioxidant pharmacological therapies for COPD.
Rahman I; MacNee W
Curr Opin Pharmacol; 2012 Jun; 12(3):256-65. PubMed ID: 22349417
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological antioxidant strategies as therapeutic interventions for COPD.
Rahman I
Biochim Biophys Acta; 2012 May; 1822(5):714-28. PubMed ID: 22101076
[TBL] [Abstract][Full Text] [Related]
12. The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease.
Hooper C; Calvert J
Int J Chron Obstruct Pulmon Dis; 2008; 3(4):659-69. PubMed ID: 19281081
[TBL] [Abstract][Full Text] [Related]
13. Variation in the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells after treatment with S-carboxymethylcysteine.
Suer E; Sayrac S; Sarinay E; Ozturk HE; Turkoz M; Ichinose A; Nagatake T; Ahmed K
J Infect Chemother; 2008 Aug; 14(4):333-6. PubMed ID: 18709541
[TBL] [Abstract][Full Text] [Related]
14. Modulating effects of mucoregulating drugs on the attachment of Haemophilus influenzae.
Ndour CT; Ahmed K; Nakagawa T; Nakano Y; Ichinose A; Tarhan G; Aikawa M; Nagatake T
Microb Pathog; 2001 Mar; 30(3):121-7. PubMed ID: 11273737
[TBL] [Abstract][Full Text] [Related]
15. The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells.
Zheng CH; Ahmed K; Rikitomi N; Martinez G; Nagatake T
Microbiol Immunol; 1999; 43(2):107-13. PubMed ID: 10229264
[TBL] [Abstract][Full Text] [Related]
16. Attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells.
Andersson B; Svanborg-Edén C
Respiration; 1989; 55 Suppl 1():49-52. PubMed ID: 2682869
[TBL] [Abstract][Full Text] [Related]
17. Activity of oral beta-lactam antimicrobial agents versus respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the era of antibiotic resistance.
Doern GV
Otolaryngol Head Neck Surg; 2002 Dec; 127(6 Suppl):S17-23. PubMed ID: 12511856
[TBL] [Abstract][Full Text] [Related]
18. S-carboxymethylcysteine inhibits the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells.
Cakan G; Turkoz M; Turan T; Ahmed K; Nagatake T
Microb Pathog; 2003 Jun; 34(6):261-5. PubMed ID: 12782478
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
